William Garrett  Gray net worth and biography

William Gray Biography and Net Worth

William Garrett Gray serves as Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary of the Company. Mr. Gray has served as our Vice President, Finance and Accounting since February 2016, as our Principal Financial Officer since December 2016, and as our Corporate Secretary since January 2018. Mr. Gray joined us from Keryx Biopharmaceuticals, Inc., a publicly traded biotechnology company, which he joined in 2013, and where he most recently served as Corporate Controller, helping grow the finance and accounting department during Keryx’s transition from a development-stage company to a fully integrated commercial organization. Prior to joining Keryx, Mr. Gray began his professional career with Deloitte & Touche, LLP, where he served as a senior auditor. Mr. Gray has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New York.

What is William Garrett Gray's net worth?

The estimated net worth of William Garrett Gray is at least $297,709.20 as of February 28th, 2024. Mr. Gray owns 145,224 shares of Checkpoint Therapeutics stock worth more than $297,709 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Gray may own. Additionally, Mr. Gray receives an annual salary of $365,750.00 as CFO at Checkpoint Therapeutics. Learn More about William Garrett Gray's net worth.

How old is William Garrett Gray?

Mr. Gray is currently 37 years old. There are 1 older executives and no younger executives at Checkpoint Therapeutics. The oldest executive at Checkpoint Therapeutics is Mr. James F. Oliviero III, C.F.A., President, CEO & Director, who is 48 years old. Learn More on William Garrett Gray's age.

What is William Garrett Gray's salary?

As the CFO of Checkpoint Therapeutics, Inc., Mr. Gray earns $365,750.00 per year. The highest earning executive at Checkpoint Therapeutics is Mr. James F. Oliviero III, C.F.A., President, CEO & Director, who commands a salary of $891,000.00 per year. Learn More on William Garrett Gray's salary.

How do I contact William Garrett Gray?

The corporate mailing address for Mr. Gray and other Checkpoint Therapeutics executives is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. Checkpoint Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on William Garrett Gray's contact information.

Has William Garrett Gray been buying or selling shares of Checkpoint Therapeutics?

During the last quarter, William Garrett Gray has sold $12,236.70 in Checkpoint Therapeutics stock. Most recently, William Garrett Gray sold 2,035 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $2.07, for a transaction totalling $4,212.45. Following the completion of the sale, the chief financial officer now directly owns 145,224 shares of the company's stock, valued at $300,613.68. Learn More on William Garrett Gray's trading history.

Are insiders buying or selling shares of Checkpoint Therapeutics?

In the last year, insiders at the sold shares 4 times. They sold a total of 23,944 shares worth more than $48,297.34. The most recent insider tranaction occured on February, 28th when CEO James F Oliviero III sold 5,894 shares worth more than $12,141.64. Insiders at Checkpoint Therapeutics own 4.4% of the company. Learn More about insider trades at Checkpoint Therapeutics.

Information on this page was last updated on 2/28/2024.

William Garrett Gray Insider Trading History at Checkpoint Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2024Sell2,035$2.07$4,212.45145,224View SEC Filing Icon  
2/1/2024Sell4,115$1.95$8,024.25147,259View SEC Filing Icon  
3/2/2023Sell3,591$5.00$17,955.0051,374View SEC Filing Icon  
2/27/2023Sell1,914$4.66$8,919.2447,465View SEC Filing Icon  
2/1/2023Sell3,154$4.79$15,107.6649,379View SEC Filing Icon  
1/10/2023Sell1,858$6.75$12,541.5052,533View SEC Filing Icon  
3/10/2022Sell3,819$18.90$72,179.10View SEC Filing Icon  
2/1/2022Sell3,706$25.10$93,020.60View SEC Filing Icon  
2/4/2021Sell2,632$36.60$96,331.20View SEC Filing Icon  
12/22/2020Sell240$27.90$6,696.00View SEC Filing Icon  
See Full Table

William Garrett Gray Buying and Selling Activity at Checkpoint Therapeutics

This chart shows William Garrett Gray's buying and selling at Checkpoint Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Checkpoint Therapeutics Company Overview

Checkpoint Therapeutics logo
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More

Today's Range

Now: $2.05
Low: $2.02
High: $2.10

50 Day Range

MA: $1.98
Low: $1.68
High: $2.32

2 Week Range

Now: $2.05
Low: $1.30
High: $3.91

Volume

345,753 shs

Average Volume

381,092 shs

Market Capitalization

$48.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1